Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Part of paid clinical trials in Tucson, Arizona.

Sponsor
CTI BioPharma
Study ID
NCT00060684
Phase
PHASE1
Status
Completed

Conditions

  • Lymphoma, Low-Grade
  • Lymphoma, Mixed-Cell, Follicular
  • Lymphoma, Small Cleaved-Cell, Follicular
  • Lymphoma, Small Lymphocytic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pixantrone (BBR 2778) — DRUG
  • fludarabine — DRUG
  • dexamethasone — DRUG
  • rituximab — DRUG

Study Details

The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.

Key Dates

Start date
Dec 31, 2001
Status verified
Sep 2008
Primary completion
Jan 31, 2005
Completion
May 31, 2007

Study Design

Enrollment
30 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Determine MTD [ Time Frame: Per cycle ]

Locations (4)

FacilityCityStateZIPSite coordinators
Arizona Clinical Research CenterTucsonArizona85712-
Greater Baltimore Medical CenterBaltimoreMaryland21204-
New Mexico Onc/Hem Consultants, Inc.AlbuquerqueNew Mexico87109-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Tucson, AZ

By research site
Arizona Clinical Research Center· Tucson, AZGreater Baltimore Medical Center· Baltimore, MDNew Mexico Onc/Hem Consultants, Inc.· Albuquerque, NMMD Anderson Cancer Center· Houston, TX

Related Studies